Shares of Anthem Inc (NYSE:ANTM) ended Wednesday session in red amid volatile trading. The shares closed down -1.05 points or -0.86% at $120.85 with 1.93 million shares getting traded. Post opening the session at $122.05, the shares hit an intraday low of $120.17 and an intraday high of $122.50 and the price vacillated in this range throughout the day. The company has a market cap of $31.07 billion and the numbers of outstanding shares have been calculated to be 263.17 million shares.
Anthem Inc (ANTM) announced that it will release third quarter 2016 financial results on November 2, 2016, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:
800-288-8975 (Domestic) 800-475-6701 (Domestic Replay)
612-332-0630 (International) 320-365-3844 (International Replay)
An access code is not required for the November 2, 2016, conference call. The access code for the replay is 378818. The replay will be available from 11:00 a.m. EDT on November 2, 2016, until the end of the day on November 16, 2016. The call will also be available through a live webcast at www.antheminc.com under the “Investors” link. A webcast replay will be available following the call.
Shares of Eli Lilly and Co (NYSE:LLY) ended Wednesday session in red amid volatile trading. The shares closed down -1.30 points or -1.59% at $80.51 with 3.63 million shares getting traded. Post opening the session at $81.81, the shares hit an intraday low of $80.46 and an intraday high of $82.22 and the price vacillated in this range throughout the day. The company has a market cap of $87.53 billion and the numbers of outstanding shares have been calculated to be 1.10 billion shares.
Eli Lilly and Co (LLY) discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications.